
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$1.94B
Market Cap
-
P/E Ratio
-0.85
EPS
$22.00
52 Week High
$9.61
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $12M |
| Total Revenue | $17M |
| Cost Of Revenue | $5.1M |
| Costof Goods And Services Sold | $5.1M |
| Operating Income | -$62M |
| Selling General And Administrative | $23M |
| Research And Development | $35M |
| Operating Expenses | $75M |
| Investment Income Net | - |
| Net Interest Income | -$19M |
| Interest Income | $3.6M |
| Interest Expense | $23M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6.4M |
| Income Before Tax | -$102M |
| Income Tax Expense | $330K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$102M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$80M |
| Ebitda | -$74M |
| Net Income | -$102M |
| Field | Value (USD) |
|---|---|
| Total Assets | $785M |
| Total Current Assets | $204M |
| Cash And Cash Equivalents At Carrying Value | $161M |
| Cash And Short Term Investments | $161M |
| Inventory | $22M |
| Current Net Receivables | $15M |
| Total Non Current Assets | $580M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $437M |
| Intangible Assets Excluding Goodwill | $437M |
| Goodwill | $134M |
| Investments | - |
| Long Term Investments | $1.4M |
| Short Term Investments | - |
| Other Current Assets | $6.1M |
| Other Non Current Assets | - |
| Total Liabilities | $187M |
| Total Current Liabilities | $103M |
| Current Accounts Payable | $19M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $57M |
| Total Non Current Liabilities | $85M |
| Capital Lease Obligations | $6.3M |
| Long Term Debt | $68M |
| Current Long Term Debt | $54M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $128M |
| Other Current Liabilities | $27M |
| Other Non Current Liabilities | $11M |
| Total Shareholder Equity | $597M |
| Treasury Stock | - |
| Retained Earnings | -$1B |
| Common Stock | $1.5B |
| Common Stock Shares Outstanding | $121M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $12M |
| Total Revenue | $17M |
| Cost Of Revenue | $5.1M |
| Costof Goods And Services Sold | $5.1M |
| Operating Income | -$62M |
| Selling General And Administrative | $23M |
| Research And Development | $35M |
| Operating Expenses | $75M |
| Investment Income Net | - |
| Net Interest Income | -$19M |
| Interest Income | $3.6M |
| Interest Expense | $23M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6.4M |
| Income Before Tax | -$102M |
| Income Tax Expense | $330K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$102M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$80M |
| Ebitda | -$74M |
| Net Income | -$102M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Mesoblast Ltd is a leading biopharmaceutical company headquartered in Melbourne, Australia, specializing in allogeneic cellular therapies aimed at addressing critical unmet medical needs. The firm is at the forefront of regenerative medicine, particularly with its innovative solutions for spine disorders, cardiovascular diseases, and inflammatory conditions, supported by robust clinical evidence. With a diverse and advanced product pipeline, Mesoblast is poised for significant growth, making it an appealing opportunity for institutional investors seeking exposure to the evolving landscape of therapeutic advancements.